Related Experiment Video

Updated: Jun 13, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

810

Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications

Larisa H Cavallari1, James C Coons2

  • 1Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, University of Florida, 1333 Center Drive, PO Box 100486, Gainesville, FL 32610, USA.

Interventional Cardiology Clinics
|September 8, 2024
PubMed

Insights

Genetic variations in CYP2C19 affect clopidogrel activation, reducing its effectiveness in about 30% of people. Alternative medications like prasugrel or ticagrelor are recommended for individuals with these genetic variants.

Area of Science:

  • Pharmacogenomics
  • Cardiology
  • Drug Metabolism

Background:

  • Clopidogrel is a prodrug requiring CYP2C19 enzyme activation.
  • Loss-of-function (LoF) polymorphisms in CYP2C19 affect approximately 30% of the population.
  • Reduced active metabolite formation leads to diminished clopidogrel effectiveness, particularly in cardiovascular patients.

Purpose of the Study:

  • To review the impact of CYP2C19 genotype on clopidogrel efficacy.
  • To highlight alternative P2Y12 inhibitors unaffected by CYP2C19 genotype.
  • To discuss the clinical implications of CYP2C19-guided antiplatelet therapy.

Main Methods:

  • Literature review of studies investigating CYP2C19 genotype and clopidogrel response.
  • Analysis of clinical outcomes in patients with and without CYP2C19 LoF alleles.
  • Comparison of alternative P2Y12 inhibitors (prasugrel, ticagrelor) in CYP2C19 genotyped populations.

Main Results:

  • Patients with CYP2C19 LoF alleles exhibit reduced clopidogrel effectiveness.
  • This reduced efficacy is associated with adverse outcomes after acute coronary syndrome or percutaneous coronary intervention.
  • Prasugrel and ticagrelor demonstrate consistent efficacy irrespective of CYP2C19 genotype.

Conclusions:

  • CYP2C19 genotype significantly influences clopidogrel response and clinical outcomes.
  • A CYP2C19-guided approach to P2Y12 inhibitor selection can improve patient outcomes.
  • Wider adoption of genotyping is warranted to optimize antiplatelet therapy in relevant patient populations.

Keywords:
CYP2C19ClopidogrelGenotypePharmacogenomicsPrasugrelTicagrelor

More Related Videos

Proteomics to Identify Proteins Interacting with P2X2 Ligand-Gated Cation Channels16:36

Proteomics to Identify Proteins Interacting with P2X2 Ligand-Gated Cation Channels

Published on: May 18, 2009

14.6K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

435

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
136
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
147
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
160
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
464
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K